$87.00
Low-dose tadalafil is a prescription medication sometimes used off-label to treat certain types of female sexual dysfunction, primarily related to arousal.
Our discrete Telehealth Service includes:
Low-dose tadalafil is being explored as a treatment option for women who experience difficulty with sexual arousal. While the active ingredient, tadalafil, is widely known as a treatment for erectile dysfunction in men, some healthcare providers prescribe it in low daily doses to help women with Female Sexual Arousal Disorder (FSAD). The goal of this off-label therapy is to improve the body’s physical response to sexual stimulation, making sexual activity more comfortable and pleasurable.
Tadalafil is a type of drug called a PDE5 inhibitor, which works by relaxing smooth muscles and increasing blood flow. In women, this action can enhance circulation to the clitoral and vaginal tissues when sexually stimulated. This increased blood flow can lead to greater sensitivity, swelling, and lubrication, which are key components of the physical arousal phase. It is important to understand that tadalafil facilitates the body’s natural response to stimulation but does not create sexual desire on its own.
The use of tadalafil for women is off-label and must be managed by a healthcare provider who can determine if it is an appropriate treatment. It is typically prescribed as a low-dose pill taken once daily. Before starting this medication, you should discuss your full medical history with your doctor, as it may not be suitable for individuals with certain heart conditions, low blood pressure, or liver and kidney issues. Tadalafil should never be taken with nitrate medications, as this can cause a dangerous drop in blood pressure. Common side effects may include headache, facial flushing, muscle aches, indigestion, and nasal congestion.
The information provided here has not been reviewed by the Food and Drug Administration. This product is not designed to diagnose, treat, cure, or prevent any disease.
Reviews
There are no reviews yet.